Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Horizon Solutions Inc

Neither a doctor nor a teaching hospital

Research payments

$4,272,551

178 payments

Through program year 2025, Horizon Solutions Inc is reported as receiving $4,272,551 in research payments, across 178 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $7,727 2
2024 Research $57,378 2
2023 Research $163,778 6
2022 Research $771,338 28
2021 Research $1,467,355 53
2020 Research $1,015,282 39
2019 Research $789,693 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $1,498,349 11 payments
  2. AstraZeneca UK Limited $1,169,672 13 payments
  3. Roche TCRC, Inc. $323,249 14 payments
  4. Amneal Pharmaceuticals LLC $300,954 33 payments
  5. Sage Therapeutics, Inc. $217,195 14 payments
  6. Ucb SA $191,271 2 payments
  7. Genzyme Corporation $181,438 18 payments
  8. Biohaven Pharmaceuticals, Inc. $147,518 23 payments
  9. Adamas Pharmaceuticals, Inc. $125,805 35 payments
  10. Sunovion Pharmaceuticals Inc. $52,378 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double-blind Placebo-controlled Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects with Parkinsons Disease $996,343 4 payments
  2. Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease $528,979 2 payments
  3. Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease $380,590 1 payment
  4. Phase II Study in Early Stage Parkinson S Disease Patients $323,249 14 payments
  5. A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations $237,427 17 payments
  6. A Phase 2, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 Monotherapy and Adjunctive Therapy With Propranolol in the Treatment of Individuals With Essential Tremor $217,195 14 payments
  7. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease $214,015 3 payments
  8. A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Ucb0599 in Patients With Parkinsons Disease PD $191,271 2 payments
  9. PO- fit-for purpose of the dgital-UPDRS in GBA-PD and iPD $170,496 15 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) $147,518 23 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $9,277 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record